Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification

NCT05259605 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1650

Last updated 2025-12-17

No results posted yet for this study

Summary

Every new classification depends on its prognostic power and on the type of treatment given. With the rapid evolution of diagnostic methods and the advance in new treatments, there is much less reliable information available on how patients with newly defined brain tumour entities should be treated and what to expect from the current treatments.

The goal is to determine whether the new 2021 WHO classification, based on cIMPACT-NOW recommendations, results in more homogeneous patient groups than the old 2016 classification. Furthermore, it will help derive provisional guidelines on how patients with these newly defined tumour entities are best treated. These recommendations will be based on the experience of EORTC investigators with chosen treatments and their experience as reported in this data collection report.

Conditions

  • Glioma
  • Glioneuronal Tumor
  • Choroid Plexus Tumor
  • Pineal Tumors
  • Germ Cell Tumor
  • Tumor of the Sellar Region
  • Diffuse Midline Glioma, H3 K27M-Mutant
  • Ependymoma
  • Embryonal Tumor
  • Pineal Tumor
  • Hemangiopericytoma
  • Hemangioblastoma
  • Melanocytic Tumor of CNS

Interventions

OTHER

Observational

The goal is to determine whether the new 2021 WHO classification, based on cIMPACT-NOW recommendations, results in more homogeneous patient groups than the old 2016 classification. Furthermore, it will help derive provisional guidelines on how patients with these newly defined tumour entities are best treated. These recommendations will be based on the experience of EORTC investigators with chosen treatments and their experience as reported in this data collection report.

Sponsors & Collaborators

  • European Organisation for Research and Treatment of Cancer - EORTC

    lead NETWORK

Principal Investigators

  • Michael Weller · EORTC Study Coordinator

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-21
Primary Completion
2027-12-30
Completion
2038-07-29

Countries

  • Austria
  • Belgium
  • France
  • Germany
  • Greece
  • Italy
  • Netherlands
  • Norway
  • Portugal
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05259605 on ClinicalTrials.gov